DK1587584T3 - Farmaceutisk kombination til profylakse eller behandling af kardiovaskulære, kardiopulmonale, pulmonale eller renale sygdomme - Google Patents
Farmaceutisk kombination til profylakse eller behandling af kardiovaskulære, kardiopulmonale, pulmonale eller renale sygdommeInfo
- Publication number
- DK1587584T3 DK1587584T3 DK04701918T DK04701918T DK1587584T3 DK 1587584 T3 DK1587584 T3 DK 1587584T3 DK 04701918 T DK04701918 T DK 04701918T DK 04701918 T DK04701918 T DK 04701918T DK 1587584 T3 DK1587584 T3 DK 1587584T3
- Authority
- DK
- Denmark
- Prior art keywords
- cardiopulmonary
- prophylaxis
- cardiovascular
- treatment
- renal diseases
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 201000006306 Cor pulmonale Diseases 0.000 title abstract 2
- 230000002612 cardiopulmonary effect Effects 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 208000019693 Lung disease Diseases 0.000 title 1
- 230000002685 pulmonary effect Effects 0.000 title 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 abstract 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 2
- 230000014509 gene expression Effects 0.000 abstract 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 2
- -1 3-hydroxy-2-methylglutaryl coenzyme A Chemical compound 0.000 abstract 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 1
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 229940123934 Reductase inhibitor Drugs 0.000 abstract 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000003257 anti-anginal effect Effects 0.000 abstract 1
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002402 anti-lipaemic effect Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000005516 coenzyme A Substances 0.000 abstract 1
- 229940093530 coenzyme a Drugs 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001553 hepatotropic effect Effects 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 1
- 229960002855 simvastatin Drugs 0.000 abstract 1
- 229960005187 telmisartan Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10301372A DE10301372A1 (de) | 2003-01-16 | 2003-01-16 | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| DE10335027A DE10335027A1 (de) | 2003-07-31 | 2003-07-31 | Verwendung von Angiotensin II Rezeptor Antagonisten |
| PCT/EP2004/000175 WO2004062729A1 (fr) | 2003-01-16 | 2004-01-14 | Composition pharmaceutique pour prevenir ou soigner des maladies cardio-vasculaires, cardio-pulmonaires, pulmonaires ou renales |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1587584T3 true DK1587584T3 (da) | 2007-09-24 |
Family
ID=32714792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04701918T DK1587584T3 (da) | 2003-01-16 | 2004-01-14 | Farmaceutisk kombination til profylakse eller behandling af kardiovaskulære, kardiopulmonale, pulmonale eller renale sygdomme |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050004193A1 (fr) |
| EP (2) | EP1818056A1 (fr) |
| JP (1) | JP2006515877A (fr) |
| KR (1) | KR20050092119A (fr) |
| AT (1) | ATE362782T1 (fr) |
| AU (1) | AU2004204353A1 (fr) |
| BR (1) | BRPI0406812A (fr) |
| CA (1) | CA2513281C (fr) |
| CY (1) | CY1106775T1 (fr) |
| DE (1) | DE502004003880D1 (fr) |
| DK (1) | DK1587584T3 (fr) |
| EA (1) | EA009886B1 (fr) |
| EC (1) | ECSP055914A (fr) |
| ES (1) | ES2287689T3 (fr) |
| HR (1) | HRP20050655A2 (fr) |
| MX (1) | MXPA05007559A (fr) |
| NO (1) | NO20053793L (fr) |
| PL (1) | PL376213A1 (fr) |
| PT (1) | PT1587584E (fr) |
| RS (1) | RS20050536A (fr) |
| SI (1) | SI1587584T1 (fr) |
| WO (1) | WO2004062729A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
| HRP20140212T1 (hr) * | 2004-11-05 | 2014-04-11 | Boehringer Ingelheim International Gmbh | Dvoslojna tableta koja sadrži telmisartan i amlodipin |
| WO2007051007A2 (fr) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combinaison de composes organiques |
| US20090030057A1 (en) * | 2005-11-22 | 2009-01-29 | Shlomit Wizel | Pharmaceutical composition of telmisartan |
| JP5558104B2 (ja) * | 2006-12-11 | 2014-07-23 | スリー−ディー マトリックス， インコーポレイテッド | 心組織の保護および再生のための組成物および方法 |
| EP2281557A4 (fr) | 2008-04-29 | 2011-08-31 | Hanall Biopharma Co Ltd | Formulation pharmaceutique contenant un agent bloquant les récepteurs de l'angiotensine ii |
| US9387249B2 (en) | 2008-12-23 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
| US9498464B2 (en) * | 2011-12-09 | 2016-11-22 | Artskin D.O.O. | Treatment of arterial wall by combination of RAAS inhibitor and HMG-CoA reductase inhibitor |
| WO2013136277A1 (fr) * | 2012-03-13 | 2013-09-19 | Unimark Remedies Ltd. | Compositions pharmaceutiques pour le traitement de maladies cardiovasculaires |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9708517A (pt) * | 1996-04-05 | 1999-08-03 | Takeda Chemical Industries Ltd | Composição farmacêutica processo para prevenir ou tratar doenças mediadas por angiotensina ii em um mamífero e uso de um composto |
| US20010006656A1 (en) * | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
| CA2382549C (fr) * | 1999-08-30 | 2005-03-15 | Aventis Pharma Deutschland Gmbh | Utilisation d'inhibiteurs du systeme renine-angiotensine dans la prevention de manifestations cardio-vasculaires |
| IL152079A0 (en) * | 2000-04-12 | 2003-05-29 | Novartis Ag | Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
| US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| AU2001284413A1 (en) * | 2000-08-30 | 2002-03-13 | Sankyo Company Limited | Medicinal compositions for preventing or treating heart failure |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| JP4585198B2 (ja) * | 2002-12-27 | 2010-11-24 | 武田薬品工業株式会社 | 体重増加抑制剤 |
-
2004
- 2004-01-14 PT PT04701918T patent/PT1587584E/pt unknown
- 2004-01-14 AU AU2004204353A patent/AU2004204353A1/en not_active Abandoned
- 2004-01-14 CA CA2513281A patent/CA2513281C/fr not_active Expired - Fee Related
- 2004-01-14 EA EA200501057A patent/EA009886B1/ru not_active IP Right Cessation
- 2004-01-14 US US10/757,015 patent/US20050004193A1/en not_active Abandoned
- 2004-01-14 SI SI200430377T patent/SI1587584T1/sl unknown
- 2004-01-14 EP EP07105299A patent/EP1818056A1/fr not_active Withdrawn
- 2004-01-14 MX MXPA05007559A patent/MXPA05007559A/es active IP Right Grant
- 2004-01-14 DK DK04701918T patent/DK1587584T3/da active
- 2004-01-14 ES ES04701918T patent/ES2287689T3/es not_active Expired - Lifetime
- 2004-01-14 BR BR0406812-2A patent/BRPI0406812A/pt not_active IP Right Cessation
- 2004-01-14 PL PL04376213A patent/PL376213A1/xx not_active Application Discontinuation
- 2004-01-14 DE DE502004003880T patent/DE502004003880D1/de not_active Expired - Lifetime
- 2004-01-14 JP JP2006500558A patent/JP2006515877A/ja active Pending
- 2004-01-14 EP EP04701918A patent/EP1587584B1/fr not_active Expired - Lifetime
- 2004-01-14 AT AT04701918T patent/ATE362782T1/de active
- 2004-01-14 HR HR20050655A patent/HRP20050655A2/xx not_active Application Discontinuation
- 2004-01-14 KR KR1020057013209A patent/KR20050092119A/ko not_active Withdrawn
- 2004-01-14 WO PCT/EP2004/000175 patent/WO2004062729A1/fr not_active Ceased
- 2004-01-14 RS YUP-2005/0536A patent/RS20050536A/sr unknown
-
2005
- 2005-07-12 EC EC2005005914A patent/ECSP055914A/es unknown
- 2005-08-10 NO NO20053793A patent/NO20053793L/no not_active Application Discontinuation
-
2007
- 2007-07-30 CY CY20071101012T patent/CY1106775T1/el unknown
-
2011
- 2011-04-13 US US13/086,131 patent/US20110190277A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1587584B1 (fr) | 2007-05-23 |
| MXPA05007559A (es) | 2005-09-21 |
| CA2513281A1 (fr) | 2004-07-29 |
| JP2006515877A (ja) | 2006-06-08 |
| HRP20050655A2 (en) | 2006-05-31 |
| AU2004204353A1 (en) | 2004-07-29 |
| SI1587584T1 (sl) | 2007-10-31 |
| EA009886B1 (ru) | 2008-04-28 |
| WO2004062729A8 (fr) | 2004-10-07 |
| EA200501057A1 (ru) | 2006-02-24 |
| CY1106775T1 (el) | 2012-05-23 |
| WO2004062729A1 (fr) | 2004-07-29 |
| DE502004003880D1 (de) | 2007-07-05 |
| ECSP055914A (es) | 2006-03-01 |
| ATE362782T1 (de) | 2007-06-15 |
| ES2287689T3 (es) | 2007-12-16 |
| US20110190277A1 (en) | 2011-08-04 |
| US20050004193A1 (en) | 2005-01-06 |
| PL376213A1 (en) | 2005-12-27 |
| EP1818056A1 (fr) | 2007-08-15 |
| CA2513281C (fr) | 2012-04-03 |
| PT1587584E (pt) | 2007-06-11 |
| KR20050092119A (ko) | 2005-09-20 |
| NO20053793L (no) | 2005-08-10 |
| BRPI0406812A (pt) | 2005-12-27 |
| EP1587584A1 (fr) | 2005-10-26 |
| RS20050536A (sr) | 2007-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL378225A1 (pl) | Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób sercowo-naczyniowych, sercowo-płucnych, płucnych lub nerek | |
| DK1587584T3 (da) | Farmaceutisk kombination til profylakse eller behandling af kardiovaskulære, kardiopulmonale, pulmonale eller renale sygdomme | |
| NO20051242L (no) | Blandinger for inhibering av protein kinase C alfa for behandling av Diabetes mellitus og kardiovaskulaere sykdommer | |
| NO20073932L (no) | Fuserte bicykliske karboksamidderivater for anvendelse som CXCR2 inhibitorer i behandlingen av inflammasjon | |
| ES2196917T3 (es) | Amidas heteroaromaticas como inhibidores del factor xa`. | |
| AR041927A1 (es) | Controlador de pie de un sistema microquirurgico | |
| ATE465146T1 (de) | 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren | |
| JP2007277267A5 (fr) | ||
| NO20034986L (no) | Furan og tiofenderivater som aktiverer human peroksisom proliferator aktiverte reseptorer | |
| ATE386715T1 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
| NO20051726L (no) | Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser | |
| WO2005082863A3 (fr) | Derives heterocycliques | |
| ATE368647T1 (de) | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) | |
| WO2004052853A3 (fr) | Derives substitues de l'acide acetique de 3-alkyle et 3-arylalkyle 1h-indol-1-yle en tant qu'inhibiteurs de l'inhibiteur des activateurs du plasminogene (pai-1) | |
| CY1110835T1 (el) | Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c | |
| DE60329330D1 (de) | Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors | |
| SE0702522L (sv) | Sammansättningar med förlängd frisättning och metoder för deras tillverkning | |
| EP1489078A4 (fr) | Derive de benzofurane | |
| DE602005016297D1 (de) | Antithrombotische diamide | |
| SE0201940D0 (sv) | New combination II | |
| AR038305A1 (es) | Composicion farmaceutica dispersable oralmente de perindopril | |
| DE602005013275D1 (de) | Pyrrolopyridin-2-karbonsäureamide | |
| AR038206A1 (es) | Composicion farmaceutica dispersable oralmente de ivabradina | |
| ATE453658T1 (de) | Konjugate mit entzündungshemmender aktivität | |
| NO20044507L (no) | 1-oksa-3-aza-dibenzoazulener som inhibitorer av tumornekrosefaktorproduksjon og mellomprodukter for fremstilling derav |